Data-driven computational analysis & simulation identified drug repurposing opportunities for CoV19

Computational Biology, Network-based algorithms, and Artificial Neural Network to predict the repositioning of 200 already approved drugs against SARS-CoV-2.

Speaker Note:
We are confident our approach has identified potential targets since 20% of these drugs are currently in COVID-19 clinical trials. We present the mechanism of action of the 200 drugs and demonstrate the efficacy of two of these (Proguanil and Sulfasalazine) in cellular assays. This huge dataset of SARS-CoV-2 induced pathways, already approved drugs to target them, along with their mechanism of action, defines a resource for repurposing of drugs against COVID-19, either in monotherapies or in combination therapy.